Company Overview
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
Why Investors Should Care
Generates a return on equity of 16.5%, reflecting efficient use of shareholder capital.
Trades at an undemanding P/E of 13.9.
Maintains a net profit margin of 25.6%.
Offers a dividend yield of 2.07%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $17.36B (-9.3% YoY); net profit $3.65B.
- Trailing 12 Months Year-on-year growth — revenue +27.9%, earnings +3860.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -3.2%, profit CAGR -6.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -3.23% |
| 1 Year: | 27.90% |
Compounded Profit Growth
| 5 Years: | -6.20% |
| 1 Year: | 3,860.00% |
Stock Price Performance
| 1 Year: | +21.41% |
| 6 Months: | +12.90% |
| 3 Months: | +9.40% |
| 1 Month: | +4.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.82 · Neutral
P/E of 13.95 is above the sector median of 13.30 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 25.6%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -3.2% CAGR over 5 years.
- Earnings shrank at -6.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AFL Aflac Incorporated SPX | 122.05 | 13.95 | $62.12B | 2.07% | - | 16.47% | -3.23% | -6.20% |
| 2 | JPM JPMorgan Chase & Co. SPX | 342.89 | 16.42 | $918.78B | 1.87% | - | 16.47% | 5.35% | 7.56% |
| 3 | BRK-B Berkshire Hathaway Inc. SPX | 491.09 | 14.61 | $686.70B | 0.00% | - | 10.50% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPX | 356.02 | 31.01 | $590.89B | 0.83% | 37.15% | 60.35% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPX | 538.02 | 31.10 | $471.86B | 0.71% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPX | 60.62 | 15.04 | $430.20B | 2.00% | - | 10.64% | 6.00% | 3.49% |
| 7 | MS Morgan Stanley SPX | 227.67 | 20.62 | $359.10B | 1.87% | - | 16.39% | 3.76% | 9.66% |
| 8 | GS The Goldman Sachs Group, Inc. SPX | 1,140.00 | 20.83 | $336.31B | 1.69% | - | 14.55% | - | 2.21% |
| 9 | WFC Wells Fargo & Company SPX | 85.29 | 13.18 | $261.00B | 2.11% | - | 12.03% | 4.02% | 15.98% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.32B | 5.45B | 5.44B | 5.72B | 5.96B | 5.31B | 5.43B | 5.51B | 5.42B | 5.46B | 5.59B | 5.58B | 5.13B | 5.66B | 5.51B | 5.54B | 5.60B | 5.16B | 5.41B | 5.67B | 5.91B | 5.87B | 5.56B | 5.24B | 5.17B | 5.32B | 4.70B | 3.95B | 4.80B | 5.17B | 4.95B | 3.78B | 5.44B | 5.14B | 2.95B | 3.45B | 4.22B | 4.79B | 4.89B | 4.41B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | 1.08B | 1.04B | 1.09B | - | 1.03B | 1.07B | 1.01B | - | 1.11B | 1.14B | 1.06B | - | 1.14B | 1.14B | 1.16B | - | 1.18B | 1.24B | 1.04B | - | 1.31B | 1.34B | 1.29B | 1.16B | 1.14B | 1.11B | - | 1.13B | 1.14B | 1.30B | - | - | - | - | 195.00M | 874.00M | 2.05B | 1.63B | 1.28B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.00M | 52.00M | 57.00M | 61.00M | 60.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 145.00M | 822.00M | 1.99B | 1.57B | 1.23B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 116.00M | 223.00M | 355.00M | 193.00M | 206.00M |
| Net Income | - | 731.00M | 548.00M | 629.00M | - | 592.00M | 713.00M | 716.00M | - | 717.00M | 832.00M | 845.00M | - | 928.00M | 817.00M | 777.00M | - | 566.00M | 805.00M | 2.46B | - | 1.29B | 1.10B | 888.00M | 1.05B | 1.39B | 1.78B | - | 1.19B | 1.63B | 1.57B | - | 1.88B | 1.75B | -93.00M | 29.00M | 599.00M | 1.64B | 1.38B | 1.02B |
| Diluted EPS | 1.71 | 1.74 | 1.32 | 1.53 | 1.84 | 0.73 | 0.89 | 0.90 | 3.27 | 0.91 | 1.07 | 1.09 | 0.69 | 1.23 | 1.09 | 1.04 | 1.06 | 0.78 | 1.12 | 3.44 | 1.35 | 1.87 | 1.62 | 1.32 | 1.60 | 2.17 | 2.82 | 0.31 | 1.94 | 2.71 | 2.64 | 0.46 | 3.25 | 3.10 | -0.17 | 0.05 | 1.11 | 3.08 | 2.64 | 1.98 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.39B | 16.55B | 18.25B | 20.73B | 22.17B | 25.36B | 23.94B | 22.73B | 20.87B | 22.56B | 21.67B | 21.76B | 22.31B | 22.15B | 21.55B | 19.15B | 18.84B | 19.13B | 17.36B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | 3.44B | 3.98B | 4.50B | 4.66B | 4.40B | 4.25B | 4.00B | 4.12B | 4.09B | 4.35B | 4.46B | 4.42B | 4.93B | 5.09B | 5.46B | 6.61B | 4.75B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 226.00M | 195.00M | 197.00M | 220.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.87B | 5.26B | 6.42B | 4.53B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 451.00M | 603.00M | 974.00M | 887.00M |
| Net Income | 1.63B | 1.25B | 1.50B | 2.33B | 1.94B | 2.87B | 3.16B | 2.95B | 2.53B | 2.66B | 4.60B | 2.92B | 3.30B | 4.78B | 4.23B | 4.42B | 4.66B | 5.44B | 3.65B |
| Diluted EPS | 3.31 | 2.62 | 3.19 | 4.92 | 4.12 | 6.11 | 6.76 | 6.50 | 5.85 | 3.21 | 5.77 | 3.77 | 4.43 | 6.67 | 6.25 | 6.93 | 7.78 | 9.63 | 6.82 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 79.33B | 84.11B | 100.24B | 116.24B | 121.31B | 121.31B | 119.73B | 118.26B | 129.82B | 137.22B | 140.41B | 152.77B | 165.09B | - | 131.74B | 126.72B | 117.57B | 116.47B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cash & Equivalents | 1.20B | 1.56B | 941.00M | 2.32B | 2.12B | 2.25B | 2.04B | 2.54B | 4.66B | 4.35B | 4.86B | 3.49B | 4.34B | 4.90B | 5.14B | - | 3.94B | 4.31B | 6.23B | 6.25B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 647.00M | 848.00M | 779.00M | 835.00M |
| Total Liabilities | - | - | 72.69B | 75.69B | 89.98B | 103.29B | 115.12B | 106.69B | 101.42B | 100.55B | 109.34B | 112.62B | 116.94B | 123.81B | 131.53B | - | 111.60B | 104.74B | 91.47B | 86.98B |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.29B | 7.24B | 7.40B | 8.33B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.44B | 7.36B | 7.50B | 8.41B |
| Total Equity | - | 8.79B | 6.64B | 8.42B | 10.54B | 12.95B | 15.98B | 14.62B | 18.35B | 17.71B | 20.48B | 24.60B | 23.46B | 28.96B | 33.56B | - | 20.14B | 21.98B | 26.10B | 29.49B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.35B | 1.36B | 1.36B | 1.36B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.66B | 4.96B | 6.16B | 6.99B | 10.84B | 14.95B | 10.55B | 6.55B | 6.78B | 5.99B | 6.13B | 6.01B | 5.46B | 5.96B | 5.05B | 3.88B | 3.19B | 2.71B | 2.56B |
| Investing Cash Flow | -3.65B | -4.28B | -5.48B | -7.43B | -10.83B | -16.95B | -11.09B | -4.24B | -4.90B | -3.85B | -5.43B | -3.58B | -3.17B | -4.62B | -2.38B | -1.54B | 817.00M | 2.78B | 1.56B |
| Financing Cash Flow | -655.00M | -1.38B | 699.00M | 161.00M | 64.00M | 1.95B | 1.14B | -147.00M | -2.19B | -1.62B | -2.06B | -1.62B | -1.71B | -1.11B | -2.74B | -3.55B | -3.72B | -3.49B | -4.07B |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.88B | 3.19B | 2.71B | 2.56B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.21B | 284.00M | 2.00B | 47.00M |
| Share Buybacks | 606.00M | 1.49B | 10.00M | 121.00M | 308.00M | 118.00M | 813.00M | 1.21B | 1.31B | 1.42B | 1.35B | 1.30B | 1.63B | 1.54B | 2.30B | 2.40B | 2.80B | 2.80B | 3.53B |
| Dividends Paid | 373.00M | 434.00M | 524.00M | 535.00M | 552.00M | 603.00M | 635.00M | 654.00M | 656.00M | 658.00M | 661.00M | 793.00M | 771.00M | 769.00M | 855.00M | 979.00M | 966.00M | 1.09B | 1.20B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | 18.8% | 19.2% | 20.3% | 18.4% | 18.4% | 18.7% | 19.2% | 18.2% | 18.9% | 20.0% | 20.0% | 19.9% | 22.9% | 26.6% | 29.0% | 34.6% | 27.4% |
| Net Margin % | 10.6% | 7.6% | 8.2% | 11.2% | 8.7% | 11.3% | 13.2% | 13.0% | 12.1% | 11.8% | 21.2% | 13.4% | 14.8% | 21.6% | 19.6% | 23.1% | 24.7% | 28.5% | 21.0% |
| ROE % | 18.6% | 18.9% | 17.8% | 22.1% | 15.0% | 17.9% | 21.6% | 16.1% | 14.3% | 13.0% | 18.7% | 12.4% | 11.4% | 14.2% | - | 21.9% | 21.2% | 20.9% | 12.4% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AFL
3 Overlooked Stocks Positioned for the Next Market Rotation
Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks gaining quiet momentum.…
GL Outperforms Industry, Trades at a Discount: How to Play the Stock?
Globe Life's premium growth, rising sales, AI initiatives and capital returns support long-term growth as underwriting discipline and investment income strengthen earnings.
Aflac (AFL) Stock Looks Rich On Its Japan Cyber Breach
Aflac stock has delivered a strong 147.0% return over the past 5 years, yet its current pricing sits between two conflicting valuation reads, with the Excess Returns intrinsic value estimate pointing to upside while traditional market multi…
3 Unpopular Stocks We Find Risky
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.…
How Aflac’s Omnibus Shelf and Fit Checks Campaign At Aflac (AFL) Has Changed Its Investment Story
Aflac recently filed an omnibus shelf registration statement covering common stock, debt securities, warrants, subscription rights, purchase contracts and purchase units, while also rolling out its Fit Checks cancer screening awareness camp…
The 3 Best Dividend Aristocrats for 2026: The Halftime Scorecard
Six months ago we named three Dividend Aristocrats as the best bets for 2026, and the halftime scorecard reveals one stock that more than doubled the market, one that held steady, and one that hit a wall hard enough to make investors questi…
AFL — Frequently Asked Questions
What is the current share price of Aflac Incorporated (AFL)?
As of 2026-07-14 21:23 PDT, Aflac Incorporated (AFL) trades at $122.05 on NYSE. Its 52-week range is $96.04 to $123.30.
What is the market capitalisation of AFL?
Aflac Incorporated (AFL) has a market capitalisation of $62.12B on NYSE.
What is the P/E ratio of AFL?
AFL trades at a trailing price-to-earnings (P/E) ratio of 13.95. The industry average P/E is 13.30. Its price-to-book (P/B) ratio is 2.01.
Does AFL pay a dividend?
Aflac Incorporated (AFL) currently offers a dividend yield of 2.07%.
What is the return on equity (ROE) of AFL?
AFL has a return on equity (ROE) of 16.47%.
Is AFL a good stock to buy?
This page provides a data-driven analysis of Aflac Incorporated (AFL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.